Compare SR & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SR | TERN |
|---|---|---|
| Founded | 1857 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.8B |
| IPO Year | N/A | 2021 |
| Metric | SR | TERN |
|---|---|---|
| Price | $88.88 | $48.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $88.11 | $48.60 |
| AVG Volume (30 Days) | 282.9K | ★ 1.8M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.60% | N/A |
| EPS Growth | N/A | ★ 11.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.19 | N/A |
| Revenue Next Year | $7.84 | N/A |
| P/E Ratio | $19.47 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $71.24 | $1.87 |
| 52 Week High | $94.27 | $49.53 |
| Indicator | SR | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 42.65 | 68.28 |
| Support Level | $81.62 | $38.99 |
| Resistance Level | $88.66 | $48.26 |
| Average True Range (ATR) | 2.01 | 2.53 |
| MACD | -0.42 | 0.32 |
| Stochastic Oscillator | 2.74 | 84.01 |
Spire Inc. is the holding company for Spire Missouri, Spire Alabama, other gas utilities, and gas-related businesses, focused on growing organically, investing in infrastructure, and advancing through innovation. Its three segments are Gas Utility, Gas Marketing, and Midstream. The Gas Utility segment is the core business and includes Spire Missouri, Spire Alabama, and Spire EnergySouth. The Gas Marketing segment includes Spire Marketing, which provides non-regulated natural gas services across the U.S. The Midstream segment includes Spire Storage, Spire STL Pipeline, and Spire MoGas Pipeline. The majority of revenue comes from Gas Utility.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.